FibroBiologics FBLG 深 沪
已收盘 08-07 16:00:00 美东时间
0.9762
-0.044
-4.29%
华盛通- 最 高1.0964
- 今 开1.04
- 成交量 15.95万股
- 最 低 0.77
- 昨 收 1.02
- 总市值 0
- 52周最高 3.965
- 市盈率 静 --
- 换手率 Infinity.00%
- 52周最低 0.185
- 委 比 0.57%
- 总股本 --
- 历史最高 55.00
- 量 比 0.70
- 振 幅 32.00%
- 历史最低 0.185
- 每 手 1
- 风险率 0.36%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多FibroBiologics Commences Up To $9M Offering Of Common Shares, Warrants
FibroBiologics, Inc. (NASDAQ: FBLG) ("FibroBiologics" or the "Company"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and
06-26 20:37
EXCLUSIVE: FibroBiologics Doses First Patients In Diabetic Foot Ulcers Clinical Trial
FibroBiologics Inc. (NASDAQ: FBLG) reports enrolling first patients in its Phase 1/2 trial for CYWC628, a fibroblast-based therapy targeting diabetic foot ulcers.
06-03 18:46
Maxim Group Downgrades FibroBiologics to Hold
Maxim Group analyst Michael Okunewitch downgrades FibroBiologics (NASDAQ:FBLG) from Buy to Hold.
05-04 20:54
Nasdaq Confirms FibroBiologics Demonstrated Compliance With All Applicable Criteria For Continued Listing
FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases
04-21 04:04
FBS Global Receives Non-Compliance Notice From Nasdaq
Ordinary shares will continue to trade on the Nasdaq Capital Market, and the Company's listing on such exchange is not affected by the receipt of the NoticeSINGAPORE, April 16, 2026 (GLOBE NEWSWIRE) -- FBS Global Limited
04-16 19:47
D. Boral Capital Downgrades FibroBiologics to Hold
D. Boral Capital analyst Jason Kolbert downgrades FibroBiologics (NASDAQ:FBLG) from Buy to Hold.
03-27 02:30
FibroBiologics Approves 1-For-20 Reverse Stock Split
The reverse stock split is expected to become effective at 12:01 a.m. Eastern Time on March 30, 2026, with trading on a split-adjusted basis beginning on The Nasdaq Capital Market upon the commencement of trading on
03-26 04:31
FibroBiologics Receives Nasdaq Compliance Extension Through April 13
FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics" or the "Company"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for
02-23 21:38
FibroBiologics Issued Canadian IP Office Patent
FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics" or the "Company"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for
02-05 21:38
